Michael B. Atkins, MD, deputy director, Georgetown-Lombardi Comprehensive Cancer Center, discusses results from the CA209-004 trial, which was a phase I study analyzing patients with advanced, unresectable melanoma treated with nivolumab (Opdivo) plus ipilimumab (Yervoy).
Video Reports
Promising Data on the Combination of Dabrafenib and Trametinib in BRAF V600-Mutant Melanoma
Ryan Sullivan, MD, associate director, Melanoma Program, Massachusetts General Hospital Cancer Center, discusses the 5-year data pooled from the phase III COMBI-d and COMBI-v trials, which each studied dabrafenib (Tafinlar) plus trametinib (Mekinist) in patients with BRAF V600–mutant unresectable or metastatic melanoma.
Dr. Long on Nivolumab/Ipilimumab in Patients With Melanoma Who Have Brain Mets
Georgina V. Long, BSc, PhD, MBBS, FRACP, co-medical director of Melanoma Institute Australia (MIA), chair of Melanoma Medical Oncology and Translational Research at MIA and Royal North Shore Hospital, University of Sydney, discusses the long-term data from the phase II ABC study (NCT02374242), in which investigators are comparing the efficacy of nivolumab (Opdivo) in combination with ipilimumab (Yervoy) versus single-agent nivolumab in patients with melanoma brain metastases.
Recommendations for Molecular Testing in Melanoma
Hussein A. Tawbi, MD, PhD: BRAF mutations occur in half of all melanoma patients. Again, they may actually carry prognostic value.